Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com -- Shares of Groep Brussel Lambert NV (ENXTBR:GBLB) edged down 1% following the release of its full-year 2024 results. While the valuation of the company’s investment portfolio met estimates, the report revealed a mixed performance in its unlisted assets, leading to a slight dip in stock value.
The company’s two largest unlisted stakes, Affidea and Sanopsis, saw their valuations increase by 7% and 10% respectively in the fourth quarter. However, these gains were tempered by a significant markdown in the valuation of Canyon, which is now valued at just 0.7 times the invested capital.
Despite higher cash balances contributing to a net asset value per share (NAVps) 1% above estimates, the markdown of Canyon seemed to weigh on investor sentiment.
In a strategic corporate move, GBL has announced the appointment of a new external CEO, previously at the helm of KKR’s EMEA business, while the current CEO will transition to the role of chairman.
This leadership change is anticipated to be positively received by the market, as noted by Citi analysts. They commented, "We expect this to be well received by investors given his extensive private markets experience. The DPS of €5.00 is in line with guidance. We do not expect GBL’s shares to move significantly at tomorrow’s open."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.